Hutchison Medipharma Enterprises

HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has built a fully integrated platform including a proprietary drug discovery engine, a global clinical development organization, and a large-scale commercial infrastructure in China. Its portfolio includes three internally developed oncology drugs—Elunate (fruquintinib), Sulanda (surufatinib), and Orpathys (savolitinib)—which are marketed in China, with fruquintinib also approved in the United States. HUTCHMED maintains strategic partnerships with global leaders such as AstraZeneca, Takeda, and Eli Lilly to accelerate the development and commercialization of its pipeline. Headquartered in Hong Kong, the company is listed on the Nasdaq and HKEX, reflecting its global reach and commitment to addressing unmet medical needs in oncology.